Do analysts rate TPST or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TPST or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Redhill Biopharma N/A N/A N/A

Do analysts recommend CELU or RDHL?

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 868.21%. Given Celularity's stronger consensus rating and higher possible upside, equities analysts clearly believe Celularity is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELU or RDHL more profitable?

Redhill Biopharma has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Redhill Biopharma N/A N/A N/A

Do analysts rate ATOS or RDHL?

Atossa Genetics currently has a consensus target price of $24.50, suggesting a potential upside of 1,055.66%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATOS or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% Redhill Biopharma N/A N/A N/A

Do analysts prefer RDHL or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is RDHL or ZIVO more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A ZIVO Bioscience N/A N/A -2,240.92%

Do analysts recommend RDHL or MAAQ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, RDHL or MAAQ?

Mana Capital Acquisition has lower revenue, but higher earnings than Redhill Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma $290K 14.54 -$430K $1.05 thousand 0.00 Mana Capital Acquisition N/A N/A N/A N/A N/A

Is RDHL or MAAQ more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Mana Capital Acquisition N/A N/A N/A

Redhill Biopharma (RDHL) Competitors

$0.81 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.04 (+5.27%)

As of 07/2/2026 07:26 PM Eastern

Compare

RDHL vs. TPST, CELU, ATOS, ZIVO, and MAAQ

Should you buy Redhill Biopharma stock or one of its competitors? MarketBeat compares Redhill Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Redhill Biopharma include Tempest Therapeutics (TPST), Celularity (CELU), Atossa Genetics (ATOS), ZIVO Bioscience (ZIVO), and Mana Capital Acquisition (MAAQ). These companies are all part of the "pharmaceutical products" industry.

How does Redhill Biopharma compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tempest Therapeutics' average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Redhill Biopharma	Neutral

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 36.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tempest Therapeutics has a beta of -1.73, meaning that its stock price is 273% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market.

Redhill Biopharma has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00

Redhill Biopharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Redhill Biopharma	N/A	N/A	N/A

Summary

Redhill Biopharma beats Tempest Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Redhill Biopharma compare to Celularity?

Celularity (NASDAQ:CELU) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

In the previous week, Celularity's average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
Redhill Biopharma	Neutral

19.0% of Celularity shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Redhill Biopharma has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.68	-$91.72M	-$3.33	N/A
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00

Celularity has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market.

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 868.21%. Given Celularity's stronger consensus rating and higher possible upside, equities analysts clearly believe Celularity is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has a net margin of 0.00% compared to Celularity's net margin of -345.45%.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Redhill Biopharma	N/A	N/A	N/A

Summary

Redhill Biopharma beats Celularity on 7 of the 13 factors compared between the two stocks.

How does Redhill Biopharma compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Redhill Biopharma has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00

Redhill Biopharma's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Redhill Biopharma	N/A	N/A	N/A

Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market.

In the previous week, Atossa Genetics had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for Redhill Biopharma. Atossa Genetics' average media sentiment score of 0.67 beat Redhill Biopharma's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Atossa Genetics	Positive
Redhill Biopharma	Neutral

Atossa Genetics currently has a consensus target price of $24.50, suggesting a potential upside of 1,055.66%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Atossa Genetics and Redhill Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to ZIVO Bioscience?

Redhill Biopharma (NASDAQ:RDHL) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
ZIVO Bioscience	N/A	N/A	-2,240.92%

Redhill Biopharma has a beta of 4.98, meaning that its share price is 398% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

In the previous week, ZIVO Bioscience had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
ZIVO Bioscience	Neutral

Redhill Biopharma has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
ZIVO Bioscience	$15.85K	1,309.78	-$7.78M	-$1.71	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Redhill Biopharma beats ZIVO Bioscience on 7 of the 11 factors compared between the two stocks.

How does Redhill Biopharma compare to Mana Capital Acquisition?

Redhill Biopharma (NASDAQ:RDHL) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Mana Capital Acquisition has lower revenue, but higher earnings than Redhill Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Mana Capital Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled Mana Capital Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Mana Capital Acquisition	Neutral

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Redhill Biopharma beats Mana Capital Acquisition on 3 of the 4 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.22M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	0.00	20.06	28.02	24.70
Price / Sales	14.54	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.98	4.32	10.96	6.46
Net Income	-$430K	$64.45M	$3.57B	$337.01M
7 Day Performance	-7.56%	2.97%	2.12%	1.69%
1 Month Performance	-21.15%	6.83%	5.25%	3.81%
1 Year Performance	-59.69%	29.07%	33.29%	23.90%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.81 flat	N/A	-59.7%	$4.22M	$290K	0.00	210	Short Interest Decrease Gap Down
TPST Tempest Therapeutics	1.24 of 5 stars	$1.11 +0.9%	N/A	-84.7%	$17.58M	N/A	N/A	20	Short Interest Decrease
CELU Celularity	1.4098 of 5 stars	$0.60 -1.4%	$6.00 +903.5%	-69.8%	$17.55M	$26.55M	N/A	220	Gap Down
ATOS Atossa Genetics	2.8581 of 5 stars	$1.93 -2.5%	$24.50 +1,169.4%	-82.9%	$17.05M	N/A	N/A	8	Gap Down
ZIVO ZIVO Bioscience	N/A	$4.03 -4.3%	N/A	-58.3%	$16.73M	$15.85K	N/A	10	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. TPST, CELU, ATOS, ZIVO, and MAAQ

How does Redhill Biopharma compare to Tempest Therapeutics?

Summary

How does Redhill Biopharma compare to Celularity?

Summary

How does Redhill Biopharma compare to Atossa Genetics?

Summary

How does Redhill Biopharma compare to ZIVO Bioscience?

Summary

How does Redhill Biopharma compare to Mana Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. TPST, CELU, ATOS, ZIVO, and MAAQ

How does Redhill Biopharma compare to Tempest Therapeutics?

Do analysts rate TPST or RDHL?

Does the media prefer TPST or RDHL?

Do insiders and institutionals hold more shares of TPST or RDHL?

Which has more risk and volatility, TPST or RDHL?

Which has preferable valuation & earnings, TPST or RDHL?

Is TPST or RDHL more profitable?

Summary

How does Redhill Biopharma compare to Celularity?

Does the media prefer CELU or RDHL?

Do institutionals & insiders hold more shares of CELU or RDHL?

Which has better valuation & earnings, CELU or RDHL?

Which has more volatility & risk, CELU or RDHL?

Do analysts recommend CELU or RDHL?

Is CELU or RDHL more profitable?

Summary

How does Redhill Biopharma compare to Atossa Genetics?

Which has better earnings & valuation, ATOS or RDHL?

Is ATOS or RDHL more profitable?

Which has more risk & volatility, ATOS or RDHL?

Does the media prefer ATOS or RDHL?

Do analysts rate ATOS or RDHL?

Do institutionals and insiders hold more shares of ATOS or RDHL?

Summary

How does Redhill Biopharma compare to ZIVO Bioscience?

Do insiders and institutionals believe in RDHL or ZIVO?

Is RDHL or ZIVO more profitable?

Which has more risk & volatility, RDHL or ZIVO?

Does the media favor RDHL or ZIVO?

Which has preferable valuation and earnings, RDHL or ZIVO?

Do analysts prefer RDHL or ZIVO?

Summary

How does Redhill Biopharma compare to Mana Capital Acquisition?

Which has better earnings & valuation, RDHL or MAAQ?

Is RDHL or MAAQ more profitable?

Do analysts recommend RDHL or MAAQ?

Does the media refer more to RDHL or MAAQ?

Do insiders and institutionals hold more shares of RDHL or MAAQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools